🇺🇸 FDA
Pipeline program

Abatacept

N01 AR070018

Phase 2 small_molecule completed

Quick answer

Abatacept for Takayasu's Arteritis is a Phase 2 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Takayasu's Arteritis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials